John Kenneth Amory
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John Kenneth Amory has a total of 482 co-authors. Here are the top co-authors by number of shared publications:
William J. Bremner
Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States
41 shared publicationsAlvin M. Matsumoto
Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA
29 shared publicationsStephanie T. Page
Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States
22 shared publications- Stephanie T. Page
Department of Medicine, University of Washington, Seattle, WA 98119, USA
22 shared publications Bradley D. Anawalt
Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States
18 shared publicationsWilliam J Bremner
Department of Medicine, University of Washington School of Medicine, Seattle, Washington
10 shared publications
Latest Publications
- Open Access
Is Low Male Fertility Adaptive? Implications for Male Infertility Research
Background: Fertile human males produce significantly fewer sperm per gram of testes than most other animals, including primates. Human's low sperm output is associated with a lower pregnancy rate per episode of intercourse and a longer time to pregnancy than in most other species. This, coupled with the concealed nature of ovulation in women, means that human couples frequently require numerous acts of intercourse to achieve a pregnancy. The reason for the low fecundability of humans is unknown. Methods: I performed a literature review examining the efficiency of spermatogenesis and time to pregnancy in humans to estimate the period of time and average number of episodes of sexual intercourse required for pregnancy. These estimates were corroborated with mathematical models. Hypotheses are suggested to explain the low fecundity of humans. Results: The average, fertile human couple has sexual intercourse 17–35 times over 2–6 months to conceive, with some fertile couples requiring longer periods of time. These numbers and time period are greater than for most other species. Among the theories that could be advanced to explain the relatively low fecundability of humans compared with other species, two will be explored here: (i) a reduction in the risk of pre‐eclampsia with repeated sexual intercourse with a single partner over several months and/or (ii) improved pair‐bonding from repeated intercourse over time leading to improved outcomes for children. Conclusions: Reduced sperm production in men may be evolutionarily adaptive. Lower fertility and longer time to conception is associated with a reduced risk of pre‐eclampsia and improved outcomes for offspring. Greater understanding of the mechanism(s) involved in the relatively low sperm output in men might provide clues to explain some types of male infertility. Additional research into the reduced efficiency of sperm output in men is warranted.
Open AccessIs Low Male Fertility Adaptive? Implications for Male Infertility Research
Background: Fertile human males produce significantly fewer sperm per gram of testes than most other animals, including primates. Human's low sperm output is associated with a lower pregnancy rate per episode of intercourse and a longer time to pregnancy than in most other species. This, coupled with the concealed nature of ovulation in women, means that human couples frequently require numerous acts of intercourse to achieve a pregnancy. The reason for the low fecundability of humans is unknown. Methods: I performed a literature review examining the efficiency of spermatogenesis and time to pregnancy in humans to estimate the period of time and average number of episodes of sexual intercourse required for pregnancy. These estimates were corroborated with mathematical models. Hypotheses are suggested to explain the low fecundity of humans. Results: The average, fertile human couple has sexual intercourse 17–35 times over 2–6 months to conceive, with some fertile couples requiring longer periods of time. These numbers and time period are greater than for most other species. Among the theories that could be advanced to explain the relatively low fecundability of humans compared with other species, two will be explored here: (i) a reduction in the risk of pre‐eclampsia with repeated sexual intercourse with a single partner over several months and/or (ii) improved pair‐bonding from repeated intercourse over time leading to improved outcomes for children. Conclusions: Reduced sperm production in men may be evolutionarily adaptive. Lower fertility and longer time to conception is associated with a reduced risk of pre‐eclampsia and improved outcomes for offspring. Greater understanding of the mechanism(s) involved in the relatively low sperm output in men might provide clues to explain some types of male infertility. Additional research into the reduced efficiency of sperm output in men is warranted.
- Open Access
Feasibility and Acceptability of a Prospective Remote Pilot Study for Assessment of Airborne Environmental Exposures and Male Fertility
Objective: To evaluate the feasibility and acceptability of serial biosampling and environmental exposure assessment in reproductive-aged men and compare participant experiences with in-person versus remote sample collection. Design: Prospective cohort pilot study. Subjects: Eighteen healthy men aged 21–44 years with no history of infertility, medical conditions or medications known to cause infertility, or prior scrotal or testicular surgery. Exposure: Indoor and personal environmental exposure monitoring using PurpleAir monitors and Fresh Air wristbands, respectively. Main Outcome Measures: Feasibility of repeated remote semen and blood collection, evaluated by participant retention and number of samples returned, and participant-reported acceptability, ease of use, discomfort, preference for at-home versus in-clinic sampling, and willingness to participate in longitudinal studies. Results: 18 participants completed the initial in-person and scheduled at-home sampling, and 16 (89%) completed subsequent remote sampling. Participants successfully collected and shipped serial capillary blood samples using homeRNA and semen samples using the Fellow Semen Analysis Kit. Participants rated both collection methods as easy to use and reported minimal discomfort with blood collection. At-home participation was preferred over in-clinic sampling, particularly for semen collection. All 16 participants completing the final survey reported willingness to participate in a similar study again. Participants were willing to provide a median of 18 semen samples (range, 2–40) and 18 blood samples (range, 5–40) over a future hypothetical study. Both home-based environmental monitoring approaches were well accepted. Conclusion: Serial remote semen and blood collection paired with environmental exposure monitoring was feasible and acceptable among reproductive-aged men. High retention, preference for at-home sampling, and willingness to provide repeated samples support this approach for larger longitudinal studies investigating environmental exposures and male reproductive health.
Open AccessFeasibility and Acceptability of a Prospective Remote Pilot Study for Assessment of Airborne Environmental Exposures and Male Fertility
Objective: To evaluate the feasibility and acceptability of serial biosampling and environmental exposure assessment in reproductive-aged men and compare participant experiences with in-person versus remote sample collection. Design: Prospective cohort pilot study. Subjects: Eighteen healthy men aged 21–44 years with no history of infertility, medical conditions or medications known to cause infertility, or prior scrotal or testicular surgery. Exposure: Indoor and personal environmental exposure monitoring using PurpleAir monitors and Fresh Air wristbands, respectively. Main Outcome Measures: Feasibility of repeated remote semen and blood collection, evaluated by participant retention and number of samples returned, and participant-reported acceptability, ease of use, discomfort, preference for at-home versus in-clinic sampling, and willingness to participate in longitudinal studies. Results: 18 participants completed the initial in-person and scheduled at-home sampling, and 16 (89%) completed subsequent remote sampling. Participants successfully collected and shipped serial capillary blood samples using homeRNA and semen samples using the Fellow Semen Analysis Kit. Participants rated both collection methods as easy to use and reported minimal discomfort with blood collection. At-home participation was preferred over in-clinic sampling, particularly for semen collection. All 16 participants completing the final survey reported willingness to participate in a similar study again. Participants were willing to provide a median of 18 semen samples (range, 2–40) and 18 blood samples (range, 5–40) over a future hypothetical study. Both home-based environmental monitoring approaches were well accepted. Conclusion: Serial remote semen and blood collection paired with environmental exposure monitoring was feasible and acceptable among reproductive-aged men. High retention, preference for at-home sampling, and willingness to provide repeated samples support this approach for larger longitudinal studies investigating environmental exposures and male reproductive health.
- Open Access
- 9 July 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (8)
Modeling cortisol and cortisone binding to corticosteroid-binding globulin and albumin based on clinical protein binding data
- 9 July 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (8)
Open AccessModeling cortisol and cortisone binding to corticosteroid-binding globulin and albumin based on clinical protein binding data
- 7 July 2026
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 36 (6) , 701-706
Isotretinoin for the treatment of severe male infertility
Purpose of review: To achieve pregnancy, men with azoospermia must currently undergo a testicular procedure to retrieve sperm for intracytoplasmic sperm injection (ICSI). However, sperm are successfully retrieved only ~50% of the time. Recently, isotretinoin administration has been investigated as a means of increasing sperm production in azoospermic men. This review explains the rationale for isotretinoin use and will update readers on the results from early studies of isotretinoin treatment of male infertility. Recent findings: Pilot studies suggest that isotretinoin treatment for 3–6 months may improve sperm production to the point of reliable ejaculated sperm in up to one quarter of men with azoospermia. Notably, response rates differ by histological sub-type, with 25–40% of men with maturation arrest exhibiting improvement, while men with Sertoli-cell only syndrome do not appear to benefit. A recent case series found that in men with cryptozoospermia, sperm production can be stimulated to levels that allow for ICSI using ejaculated samples in about half of men, thus obviating the need for testicular sperm retrieval procedures. Summary: Isotretinoin therapy may improve sperm production in a subset of men with severe infertility. A fuller understanding of which men will benefit from isotretinoin will require larger studies.
- 7 July 2026
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 36 (6) , 701-706
Isotretinoin for the treatment of severe male infertility
Purpose of review: To achieve pregnancy, men with azoospermia must currently undergo a testicular procedure to retrieve sperm for intracytoplasmic sperm injection (ICSI). However, sperm are successfully retrieved only ~50% of the time. Recently, isotretinoin administration has been investigated as a means of increasing sperm production in azoospermic men. This review explains the rationale for isotretinoin use and will update readers on the results from early studies of isotretinoin treatment of male infertility. Recent findings: Pilot studies suggest that isotretinoin treatment for 3–6 months may improve sperm production to the point of reliable ejaculated sperm in up to one quarter of men with azoospermia. Notably, response rates differ by histological sub-type, with 25–40% of men with maturation arrest exhibiting improvement, while men with Sertoli-cell only syndrome do not appear to benefit. A recent case series found that in men with cryptozoospermia, sperm production can be stimulated to levels that allow for ICSI using ejaculated samples in about half of men, thus obviating the need for testicular sperm retrieval procedures. Summary: Isotretinoin therapy may improve sperm production in a subset of men with severe infertility. A fuller understanding of which men will benefit from isotretinoin will require larger studies.
- Open Access
Investigation of an ALDH1A1-Specific Inhibitor, FSI-TN42, as a Treatment for Obesity in Female Mice
Background/Objectives: Retinoic acids (RA) are involved in regulation of weight and energy metabolism. Mice lacking a RA synthesis enzyme, ALDH1A1, are resistant to diet-induced obesity. We previously identified an ALDH1A1-specific inhibitor, FSI-TN42 (N42), and demonstrated its efficacy in suppressing weight gain in male C57BL/6 mice fed a high-fat diet (HFD). In this report, we evaluated whether N42 is similarly effective in female mice. Methods: Two studies were performed. In the first study, C57BL/6 female mice were fed a HFD for 12 weeks to induce obesity, after which half were switched to a HFD supplemented with N42 (1 g/kg diet). A control group of mice was maintained on a low-fat purified diet throughout the study. Body weight was determined weekly, and fasting or fed blood glucose was determined at 4–8-week intervals. In the second study, obese female C57BL/6 mice were transitioned from a HFD to either (1) a moderate-fat diet (MFD) or (2) MFD + N42 for 9 weeks. Results: N42 significantly suppressed weight gain in female mice maintained on a HFD. However, it did not enhance weight loss when administered alongside a MFD diet, which alone induced significant weight loss comparable to mice fed a control diet throughout the study. Conclusions: The ALDH1A1 inhibitor N42 suppresses weight gain in female mice, consistent with prior findings in male mice. However, unlike in males, N42 did not enhance weight loss under conditions of caloric reduction, likely due to more profound weight loss induced by the lower-calorie diet in female mice.
Open AccessInvestigation of an ALDH1A1-Specific Inhibitor, FSI-TN42, as a Treatment for Obesity in Female Mice
Background/Objectives: Retinoic acids (RA) are involved in regulation of weight and energy metabolism. Mice lacking a RA synthesis enzyme, ALDH1A1, are resistant to diet-induced obesity. We previously identified an ALDH1A1-specific inhibitor, FSI-TN42 (N42), and demonstrated its efficacy in suppressing weight gain in male C57BL/6 mice fed a high-fat diet (HFD). In this report, we evaluated whether N42 is similarly effective in female mice. Methods: Two studies were performed. In the first study, C57BL/6 female mice were fed a HFD for 12 weeks to induce obesity, after which half were switched to a HFD supplemented with N42 (1 g/kg diet). A control group of mice was maintained on a low-fat purified diet throughout the study. Body weight was determined weekly, and fasting or fed blood glucose was determined at 4–8-week intervals. In the second study, obese female C57BL/6 mice were transitioned from a HFD to either (1) a moderate-fat diet (MFD) or (2) MFD + N42 for 9 weeks. Results: N42 significantly suppressed weight gain in female mice maintained on a HFD. However, it did not enhance weight loss when administered alongside a MFD diet, which alone induced significant weight loss comparable to mice fed a control diet throughout the study. Conclusions: The ALDH1A1 inhibitor N42 suppresses weight gain in female mice, consistent with prior findings in male mice. However, unlike in males, N42 did not enhance weight loss under conditions of caloric reduction, likely due to more profound weight loss induced by the lower-calorie diet in female mice.
- Open Access
Kinetics of cortisol and cortisone binding to corticosteroid binding globulin and albumin in vivo
Cortisol is a major endogenous glucocorticoid that regulates numerous physiological processes. In plasma, cortisol and its inactive metabolite cortisone bind to corticosteroid-binding globulin (CBG) and albumin, leaving only the unbound fraction available for receptor activation and metabolism. Changes in ligand or protein concentrations alter unbound fractions. Existing binding equations are difficult to extend to multi-ligand, multi-protein systems and do not readily capture competitive endogenous binding interactions. The goal of this study was to develop a plasma protein binding model that quantitatively describes binding species and predicts unbound concentrations across physiological states. Total and unbound cortisol and cortisone, CBG and albumin were measured in plasma from healthy premenopausal women (n=13) at baseline and after 7 days of 30 mg hydrocortisone treatment. Reversible 1:1 binding models were implemented in COPASI and MATLAB/Simulink, and dissociation constants (Kd) were estimated by fitting binding models to observed unbound concentrations. A model describing simultaneous binding of cortisol and cortisone to CBG and albumin yielded in vivo Kd values for cortisol:CBG, cortisone:CBG, cortisol:albumin, and cortisone:albumin of 0.0130 μM, 0.169 μM, 172 μM, and 519 μM, respectively. Model predictions agreed with observed unbound cortisol and cortisone, and bootstrap resampling confirmed stable Kd estimates. This work provides a quantitative framework for predicting unbound cortisol and cortisone across physiological and disease states by accounting for both changes in ligand and protein concentrations. This enables extrapolation without reparameterization and supports exploration of conditions such as pregnancy, adrenal insufficiency, and liver disease, informing interpretation of altered cortisol concentrations in these populations.
Open AccessKinetics of cortisol and cortisone binding to corticosteroid binding globulin and albumin in vivo
Cortisol is a major endogenous glucocorticoid that regulates numerous physiological processes. In plasma, cortisol and its inactive metabolite cortisone bind to corticosteroid-binding globulin (CBG) and albumin, leaving only the unbound fraction available for receptor activation and metabolism. Changes in ligand or protein concentrations alter unbound fractions. Existing binding equations are difficult to extend to multi-ligand, multi-protein systems and do not readily capture competitive endogenous binding interactions. The goal of this study was to develop a plasma protein binding model that quantitatively describes binding species and predicts unbound concentrations across physiological states. Total and unbound cortisol and cortisone, CBG and albumin were measured in plasma from healthy premenopausal women (n=13) at baseline and after 7 days of 30 mg hydrocortisone treatment. Reversible 1:1 binding models were implemented in COPASI and MATLAB/Simulink, and dissociation constants (Kd) were estimated by fitting binding models to observed unbound concentrations. A model describing simultaneous binding of cortisol and cortisone to CBG and albumin yielded in vivo Kd values for cortisol:CBG, cortisone:CBG, cortisol:albumin, and cortisone:albumin of 0.0130 μM, 0.169 μM, 172 μM, and 519 μM, respectively. Model predictions agreed with observed unbound cortisol and cortisone, and bootstrap resampling confirmed stable Kd estimates. This work provides a quantitative framework for predicting unbound cortisol and cortisone across physiological and disease states by accounting for both changes in ligand and protein concentrations. This enables extrapolation without reparameterization and supports exploration of conditions such as pregnancy, adrenal insufficiency, and liver disease, informing interpretation of altered cortisol concentrations in these populations.
- Open Access
Cyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice
Background: Retinoic acid plays a critical role in spermatogenesis during both spermatogonial differentiation and spermiation. Mice lacking enzymes that synthesize retinoic acid, Aldh1a1/1a2 , in the testes are infertile. WIN 18,446 reversibly inhibits spermatogenesis by inhibiting ALDH1A1/1A2 and is a promising approach to male contraception. Previously, we demonstrated the kinetics, efficacy, and reversibility of continuous treatment with WIN18,446 as a male contraceptive. Objective: We sought to investigate whether cyclic administration of WIN 18,446 could be as effective at inhibiting spermatogenesis as continuous treatment with WIN 18,446 while reducing the risk of potential testicular damage from continuous treatment. We studied testicular histology and sperm counts in response to continuous vs. cyclic treatment of WIN 18,446 and assessed recovery from the two treatment regimens. Materials and methods: Male mice were fed a diet containing WIN 18,446 for 15 weeks, followed by a diet without the drug for up to 16 weeks. For cyclic treatment, male mice were fed the WIN 18,446‐containing diet for 4 weeks, followed by three cycles of 2‐weeks of control diet, followed by 2‐weeks of WIN 18,446 diet for 12 additional weeks. After the last cyclic treatment, drug treatment was discontinued, and animals were allowed to recover for 8 weeks. Mice were euthanized at predetermined time points to assess recovery of spermatogenesis by testicular histology and sperm counts. Results: Testis weights and sperm counts were similar between cyclically treated mice and mice treated with WIN 18,446 continuously for 15 weeks. Testes of mice under cyclic treatment contained spermatocytes/spermatids, but not mature, normal spermatozoa, while those from the mice under continuous treatment had only spermatogonia. Importantly, spermatogenesis recovered more quickly when mice were treated cyclically compared to those receiving continuous treatment based on testes weight and histology. Conclusions: Cyclic treatment of mice with the ALDH1A inhibitor WIN 18,446 is as efficacious as continuous treatment in suppressing spermatogenesis and may allow for faster recovery of spermatogenesis after the cessation of drug treatment, and reduce the chance of injury to the testes from continuous treatment.
Open AccessCyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice
Background: Retinoic acid plays a critical role in spermatogenesis during both spermatogonial differentiation and spermiation. Mice lacking enzymes that synthesize retinoic acid, Aldh1a1/1a2 , in the testes are infertile. WIN 18,446 reversibly inhibits spermatogenesis by inhibiting ALDH1A1/1A2 and is a promising approach to male contraception. Previously, we demonstrated the kinetics, efficacy, and reversibility of continuous treatment with WIN18,446 as a male contraceptive. Objective: We sought to investigate whether cyclic administration of WIN 18,446 could be as effective at inhibiting spermatogenesis as continuous treatment with WIN 18,446 while reducing the risk of potential testicular damage from continuous treatment. We studied testicular histology and sperm counts in response to continuous vs. cyclic treatment of WIN 18,446 and assessed recovery from the two treatment regimens. Materials and methods: Male mice were fed a diet containing WIN 18,446 for 15 weeks, followed by a diet without the drug for up to 16 weeks. For cyclic treatment, male mice were fed the WIN 18,446‐containing diet for 4 weeks, followed by three cycles of 2‐weeks of control diet, followed by 2‐weeks of WIN 18,446 diet for 12 additional weeks. After the last cyclic treatment, drug treatment was discontinued, and animals were allowed to recover for 8 weeks. Mice were euthanized at predetermined time points to assess recovery of spermatogenesis by testicular histology and sperm counts. Results: Testis weights and sperm counts were similar between cyclically treated mice and mice treated with WIN 18,446 continuously for 15 weeks. Testes of mice under cyclic treatment contained spermatocytes/spermatids, but not mature, normal spermatozoa, while those from the mice under continuous treatment had only spermatogonia. Importantly, spermatogenesis recovered more quickly when mice were treated cyclically compared to those receiving continuous treatment based on testes weight and histology. Conclusions: Cyclic treatment of mice with the ALDH1A inhibitor WIN 18,446 is as efficacious as continuous treatment in suppressing spermatogenesis and may allow for faster recovery of spermatogenesis after the cessation of drug treatment, and reduce the chance of injury to the testes from continuous treatment.
- Open Access
- 11 August 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (9) , 100144
Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism
- 11 August 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (9) , 100144
Open AccessCurcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism
- 9 August 2025
- Published by Springer Nature
- p. 519-534
Testosterone Replacement Therapy
- Open Access
- 19 July 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (8) , 2793-2799
Treatment with isotretinoin can improve de novo sperm production in nonobstructive azoospermia or cryptozoospermia
Purpose Retinoic acid (RA), a metabolite of vitamin A, is required for mammalian spermatogenesis. Clinically, intratesticular RA concentrations are lower in infertile men. In pilot studies, RA treatment is associated with increased ejaculated sperm counts in men with oligospermia and with de novo ejaculated sperm in nonobstructive azoospermia (NOA). We evaluated whether oral isotretinoin could improve sperm production in men with NOA and cryptozoospermia. Methods Single-center, prospective, repeated measures analysis of infertile men with NOA or cryptozoospermia who received isotretinoin (20 mg twice daily) and had metabolic and semen evaluations over 3–9 months. All etiologies of infertility were included, as were subjects with prior sperm retrieval procedures. The primary endpoint was attaining reliable motile ejaculated sperm for IVF-ICSI. Results Among n = 30 consecutive men undergoing isotretinoin treatment, 26 (87%) were azoospermic and 4 (13%) were intermittently cryptozoospermic. Among azoospermic men, 24 (92%) had prior testicular procedures and 6 (23%) had a history of cryptozoospermia. Overall, 11/30 (37%) of patients developed reliable, motile ejaculated sperm counts with treatment. When evaluating biopsy histology, those with maturation arrest patterns had the highest response (6/11 or 54%) to therapy. Side effects included 30 (100%) men with dry skin/chapped lips, 4 (13%) rashes, 14 (47%) irritability, and 5 (17%) with altered cholesterol panels. Conclusion Intratesticular retinoic acid deficiency may underlie some forms of severe male factor infertility. Treatment with isotretinoin increases sperm production in some men with NOA or cryptozoospermia to the point of obviating the need for testicular sperm retrieval procedures.
- 19 July 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (8) , 2793-2799
Open AccessTreatment with isotretinoin can improve de novo sperm production in nonobstructive azoospermia or cryptozoospermia
Purpose Retinoic acid (RA), a metabolite of vitamin A, is required for mammalian spermatogenesis. Clinically, intratesticular RA concentrations are lower in infertile men. In pilot studies, RA treatment is associated with increased ejaculated sperm counts in men with oligospermia and with de novo ejaculated sperm in nonobstructive azoospermia (NOA). We evaluated whether oral isotretinoin could improve sperm production in men with NOA and cryptozoospermia. Methods Single-center, prospective, repeated measures analysis of infertile men with NOA or cryptozoospermia who received isotretinoin (20 mg twice daily) and had metabolic and semen evaluations over 3–9 months. All etiologies of infertility were included, as were subjects with prior sperm retrieval procedures. The primary endpoint was attaining reliable motile ejaculated sperm for IVF-ICSI. Results Among n = 30 consecutive men undergoing isotretinoin treatment, 26 (87%) were azoospermic and 4 (13%) were intermittently cryptozoospermic. Among azoospermic men, 24 (92%) had prior testicular procedures and 6 (23%) had a history of cryptozoospermia. Overall, 11/30 (37%) of patients developed reliable, motile ejaculated sperm counts with treatment. When evaluating biopsy histology, those with maturation arrest patterns had the highest response (6/11 or 54%) to therapy. Side effects included 30 (100%) men with dry skin/chapped lips, 4 (13%) rashes, 14 (47%) irritability, and 5 (17%) with altered cholesterol panels. Conclusion Intratesticular retinoic acid deficiency may underlie some forms of severe male factor infertility. Treatment with isotretinoin increases sperm production in some men with NOA or cryptozoospermia to the point of obviating the need for testicular sperm retrieval procedures.